Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood

HIV Clinical Trials

Volumn 7, Issue 5, 2006, Pages 263-269

  Chi, Benjamin H ^a,b,d   Lee, Alison ^a   Acosta, Edward P ^b   Westerman, Larry E ^a,b   Sinkala, Moses ^a,c   Stringer, Jeffrey S A ^a,b  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Lusaka District Health Management Board   (Zambia)

^d NONE   (Zambia)

Author keywords

HIV; Nevirapine; PMTCT; Prevention of mother to child transmission of HIV; Surveillance; Thin layer chromatography

Indexed keywords

NEVIRAPINE;

ALGORITHM; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DELIVERY; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; THIN LAYER CHROMATOGRAPHY; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION;

EID: 33845717768     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0705-263     Document Type: Article

References (18)

1. UNAIDS. 2006 report on the global AIDS epidemic. Available at: http://www.unaids.org/en/HIV⊣ta/2006GlobalReport/default.asp. Accessed September 14, 2006.
2. United Nations General Assembly Special Session on HIV/AIDS. Declaration of commitment on HIV/AIDS. August 2, 2001. Available at: http://www.un.org/ga/aids/docs/aress262.pdf. Accessed September 14, 2006.
3. Painter TM, Diaby KL, Matia DM, et al. Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study. BMJ. 2004;329(7465):543.
4. Thierman S, Chi BH, Levy JW, Sinkala M, Goldenberg RL, Stringer JS. Individual-level predictors for HIV testing among antenatal attendees in Lusaka, Zambia. Am J Med Sci. 2006;332(1):13-17.
5. Meda N, Leroy V, Viho I, et al. Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16(17)2323-2328.
6. Stringer JS, Sinkala M, Goldenberg R, Vermund S, Acosta E. Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1. Lancet. 2003;362(9384):667.
7. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362(9387):859-868.
8. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795-802.
9. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187(5):725-735.
10. Stringer JS, Sinkala M, Chapman V, et al. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS. 2003;17(11):1659-1665.
11. Chi BH, Wang L, Read JS, et al. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024*. AIDS. 2005;19(16):1857-1864.
12. Stringer JS, Sinkala M, Maclean CC, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005;19(12):1309-1315.
13. Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, Acosta EP. Detection of nevirapine in plasma using thin-layer chromatography. J Acquir Immune Defic Syndr. 2004;35(2):155-157.
14. Stringer EM, Sinkala M, Ng'uni C, et al. In an urban African setting, the cost-effectiveness of PMTCT services improves as services expands. In: Program and abstracts of the XV International AIDS Conference; 2004; Bangkok, Thailand. Abstract TuPeC4933.
15. Stringer JS, Sinkala M, Stout JP, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr. 2003;32(5):506-513.
16. Dailly E, Thomas L, Kergueris MF, Jolliet P, Bourin M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B Biomed Sci Appl. 2001;758(2):129-135.
17. Stringer JS, Sinkala M, Goldenberg RL, et al. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS. 2004;18(6):939-943.
18. Albrecht S, Semrau K, Kasonde P, et al. Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. J Acquir Immune Defic Syndr. 2006;41(1):114-118.